Purple Biotech (PPBT) expands CAPTN-3 portfolio with IM1305 tri-specific TROP2 antibody

Rhea-AI Filing Summary

Purple Biotech Ltd. reported that it has expanded its CAPTN-3 portfolio by adding IM1305, described as a novel tri-specific antibody targeting TROP2. This update was communicated through a press release titled “Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2”, which is furnished as an exhibit to the report. The filing formally records this development for investors and provides official access to the accompanying press release.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/03/2025 - 07:10 AM Learn about SEC filing dates

FAQ

What did Purple Biotech Ltd. (PPBT) report in this 6-K?

Purple Biotech Ltd. reported that it issued a press release titled “Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2.”

What is IM1305 in Purple Biotech Ltd. (PPBT)'s recent update?

IM1305 is described as a novel tri-specific antibody targeting TROP2, added to Purple Biotech’s CAPTN-3 portfolio.

How did Purple Biotech (PPBT) describe the CAPTN-3 portfolio change?

Purple Biotech stated that it is expanding its CAPTN-3 portfolio with IM1305, the new tri-specific antibody targeting TROP2.

Where can investors find more details on Purple Biotech (PPBT)'s IM1305 announcement?

Further details are provided in the press release furnished as Exhibit 99.1 titled “Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2.”

Who signed the Purple Biotech Ltd. (PPBT) 6-K related to IM1305?

The report was signed on behalf of Purple Biotech Ltd. by Gil Efron, Chief Executive Officer.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒       Form 40-F ☐

Purple Biotech

On September 3, 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued a press release “Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

September 3, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2